Haloperidol EP Impurity D (Haloperidol USP Related Compound A)(CAS: 67987-08-0)

Haloperidol EP Impurity D (CAS: 67987-08-0) is subject to regulatory guidelines such as REACH in the EU, which requires registration of substances above one tonne per year. In the US, the FDA regulates its use in pharmaceuticals, while OSHA and EPA have standards for workplace safety and environmental protection, respectively. Additionally, it must comply with the Globally Harmonized System (GHS) for classification and labelling of chemicals.

In the synthesis of haloperidol-related compounds, alternatives to Haloperidol EP Impurity D (CAS: 67987-08-0) include the use of other related impurities such as Haloperidol USP Related Compound A. Other synthetic strategies might involve the use of different reagents or catalysts, such as various amines or metal complexes, to achieve the desired chemical transformations.

The market for Haloperidol EP Impurity D (CAS: 67987-08-0) is driven by ongoing research and development in haloperidol pharmaceuticals, particularly in the areas of drug metabolism and pharmacokinetics. Trends in research include developing more selective and less toxic derivatives, which could impact the demand for related impurities. Additionally, there is a growing emphasis on environmental and safety considerations, influencing the choice of impurities in the production process.

Waste containing Haloperidol EP Impurity D (CAS: 67987-08-0) should be handled according to hazardous waste regulations. This typically involves collecting it in appropriate containers, ensuring proper labeling, and disposing of it through a licensed hazardous waste disposal service. Incineration is a common method, but it must be conducted at facilities that comply with environmental regulations to prevent harmful emissions. Additionally, precautions should be taken to protect the environment and human health during the handling and disposal process.